journal article·2019Open access

Dual targeting of folate receptor-expressing glioma tumor-associated macrophages and epithelial cells in the brain using a carbon nanosphere–cationic folate nanoconjugate

Chandra Kumar Elechalawar, Dwaipayan Bhattacharya, Mohammed Tanveer Ahmed, Halley Gora, Kathyayani Sridharan, Piyush Chaturbedy, Sarmistha Halder Sinha, Madhan Mohan Chandra Sekhar Jaggarapu, Kumar Pranav Narayan, Sumana Chakravarty, Muthusamy Eswaramoorthy, Tapas Kumar Kundu, Rajkumar Banerjee

Nanoscale Advances· Volume 1· Issue 9

Abstract

FRs. A doxorubicin-associated FR-targeting formulation (CFD), in an orthotopic glioma model and in a glioma subcutaneous model, induced the maximum anticancer effect with enhanced average mice survivability twice that of untreated mice and without any systemic liver toxicity. Additionally, we observed a significant decrease of TAM-released pro-aggressive factors, TGF-β, STAT3, invasion and migration related sICAM-1, and other cytokines indicating anti-TAM activity of the CFD. Taken together, we principally devised, to the best of our knowledge, the first FR-targeting nano-delivery system for targeting brain-associated TAMs and tumor cells as an efficient glioma therapeutic.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immune cells in cancer · MicroRNA in disease regulation · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Applied Biology Division

CSIR-Indian Institute of Chemical Technology

Hyderabad

India

Academy of Scientific & Innovative Research (AcSIR)

Department of Biological Sciences

Chemistry and Physics of Materials Unit

Jawaharlal Nehru Centre for Advanced Scientific Research

Bangalore

Transcription and Disease Laboratory

Molecular Biology and Genetics Unit

BITS Pilani

Hyderabad 500078

References (50)

Show source-provided references
1. Bai · Trends Mol. Med. · 2011 · 17 · 30110.1016/j.molmed.2011.01.011 ↗
2. Lewis · Cancer Res. · 2006 · 66 · 60510.1158/0008-5472.CAN-05-4005 ↗
3. Elgert · J. Leukocyte Biol. · 1998 · 64 · 27510.1002/jlb.64.3.275 ↗
4. Sunderkötter · Pharmacol. Ther. · 1991 · 51 · 19510.1016/0163-7258(91)90077-Y ↗
5. Zhou · Nat. Cell Biol. · 2015 · 17 · 17010.1038/ncb3090 ↗
6. Murdoch · Blood · 2004 · 104 · 222410.1182/blood-2004-03-1109 ↗
7. Pyonteck · Nat. Med. · 2013 · 19 · 126410.1038/nm.3337 ↗
8. Quail · Science · 2016 · 352
9. Chong · J. Cell. Physiol. · 1999 · 178 · 27510.1002/(SICI)1097-4652(199903)178:3<275::AID-JCP1>3.0.CO;2-Q ↗
10. Wan · Gastroenterology · 2014 · 147 · 139310.1053/j.gastro.2014.08.039 ↗
11. Miller · Nat. Commun. · 2015 · 6 · 869210.1038/ncomms9692 ↗
12. Zhang · Chem. Commun. · 2015 · 51 · 924610.1039/C5CC01759A ↗
13. Nieto-Márquez · J. Mater. Chem. · 2011 · 21 · 166410.1039/C0JM01350A ↗
14. Selvi · Nano Lett. · 2008 · 8 · 318210.1021/nl801503m ↗
15. Saul · J. Controlled Release · 2003 · 92 · 4910.1016/S0168-3659(03)00295-5 ↗
16. Puig-Kröger · Cancer Res. · 2009 · 69 · 939510.1158/0008-5472.CAN-09-2050 ↗
17. Cheng · Biomaterials · 2012 · 33 · 117010.1016/j.biomaterials.2011.10.057 ↗
18. Chen · ACS Appl. Mater. Interfaces · 2014 · 6 · 1985010.1021/am505223t ↗
19. Chen · J. Controlled Release · 2015 · 211 · 5310.1016/j.jconrel.2015.05.288 ↗
20. Gao · Sci. Rep. · 2013 · 3 · 253410.1038/srep02534 ↗
21. Wang · Adv. Funct. Mater. · 2016 · 26 · 787310.1002/adfm.201602810 ↗
22. Zeng · Adv. Funct. Mater. · 2016 · 26 · 420110.1002/adfm.201600642 ↗
23. Elechalawar · Biomater. Sci. · 2017 · 5 · 189810.1039/C7BM00405B ↗
24. Okada · Int. J. Cancer · 1998 · 78 · 19610.1002/(SICI)1097-0215(19981005)78:2<196::AID-IJC13>3.0.CO;2-9 ↗
25. Cassetta · Adv. Exp. Med. Biol. · 2016 · 21110.1007/978-3-319-26666-4_12 ↗
26. Laoui · Bio-Protoc. · 2014 · 4 · e129410.21769/BioProtoc.1294 ↗
27. Quatromoni · Am. J. Transl. Res. · 2012 · 4 · 376
28. Noy · Immunity · 2014 · 41 · 4910.1016/j.immuni.2014.06.010 ↗
29. Hao · Clin. Dev. Immunol. · 2012 · 2012
30. Panse · Br. J. Cancer · 2008 · 99 · 93010.1038/sj.bjc.6604621 ↗
31. Nitta · Oncol. Rep. · 2014 · 32 · 171510.3892/or.2014.3341 ↗
32. Rosette · Carcinogenesis · 2005 · 26 · 94310.1093/carcin/bgi070 ↗
33. Teicher · Clin. Cancer Res. · 2010 · 16 · 292710.1158/1078-0432.CCR-09-2329 ↗
34. Gong · PLoS One · 2013 · 8 · e7736610.1371/journal.pone.0077366 ↗
35. Voronov · Proc. Natl. Acad. Sci. · 2003 · 100 · 264510.1073/pnas.0437939100 ↗
36. Perrier · FEBS Lett. · 2006 · 580 · 628910.1016/j.febslet.2006.10.061 ↗
37. Belperio · J. Leukocyte Biol. · 2000 · 68 · 110.1189/jlb.68.1.1 ↗
38. Kajitani · Breast Cancer Res. Treat. · 2012 · 134 · 13910.1007/s10549-011-1944-x ↗
39. Kumar · Nature · 2007 · 448 · 3910.1038/nature05901 ↗
40. Son · J. Controlled Release · 2011 · 155 · 1810.1016/j.jconrel.2010.08.011 ↗
41. Zhan · Mol. Pharm. · 2010 · 7 · 194010.1021/mp100238j ↗
42. Wei · Angew. Chem., Int. Ed. · 2015 · 54 · 302310.1002/anie.201411226 ↗
43. Desgrosellier · Nat. Rev. Cancer · 2010 · 10 · 910.1038/nrc2748 ↗
44. Miura · ACS Nano · 2013 · 7 · 858310.1021/nn402662d ↗
45. Martinez · Annu. Rev. Immunol. · 2009 · 27 · 45110.1146/annurev.immunol.021908.132532 ↗
46. Georgoudaki · Cell Rep. · 2016 · 15 · 200010.1016/j.celrep.2016.04.084 ↗
47. Wu · Pharm. Res. · 1999 · 16 · 41510.1023/A:1018829920158 ↗
48. Varghese · Mol. Pharm. · 2007 · 4 · 67910.1021/mp0700615 ↗
49. Lu · Adv. Drug Delivery Rev. · 2004 · 56 · 116110.1016/j.addr.2004.01.009 ↗
50. Xia · Blood · 2009 · 113 · 43810.1182/blood-2008-04-150789 ↗